Stay updated with breaking news from Philip Jacoby. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/WTAQJMISB5NCFKHCHNBGYUPK3A.jpg)
A derivatives committee ruled on Monday that a bankruptcy credit event had not occurred in relation to Credit Suisse, quashing investors' efforts to trigger a payout on credit insurance linked to the Swiss lender.
Last week the Commission filed a series of cases tied to crypto assets and touting. A pending civil injunctive action was brought against Chinese…
/cloudfront-us-east-2.images.arcpublishing.com/reuters/TBWXKI7MT5LCHF237GIG6HK5RM.jpg)
One of the largest investors of the Credit Suisse bonds that were wiped out in the UBS takeover of the troubled Swiss bank still believes in the value of the debt class and the "bail-in" system designed to save banks seen as too big to fail.
ADVERTISEMENT ADVERTISEMENT Biotech's Former Brass Fights SEC Efforts To Get Court Wins Law360 (December 14, 2020, 8:36 PM EST) -- Attorneys for the former CEO and CFO of biotechnology company Osiris Therapeutics Inc. on Monday tried to rebuff the U.S. Securities and Exchange Commission's efforts to secure partial judgments against them, claiming the agency was relying on thin evidence to prove the executives cooked the company's books. At a Maryland federal court hearing via videoconference, attorneys for Osiris' ex-CEO Lode Debrabandere and ex-CFO Philip Jacoby claimed the SEC was relying ...